Jolanta Węgłowska
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Pharmaceutical studies and practices, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis(2015)792 cited
- → The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis(2017)181 cited
- → Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study(2017)136 cited
- → Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)(2018)130 cited
- → Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis(2023)127 cited
- → A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea(2019)68 cited
- → Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis(2022)40 cited
- → Sun Protection in Renal Transplant Recipients: Urgent Need for Education(2005)37 cited
- → Hypohidrotic ectodermal dysplasia(2020)9 cited
- → 002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis(2017)6 cited